{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:32:22Z","timestamp":1785591142369,"version":"3.56.0"},"reference-count":78,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>In Japan, there is concern regarding the relation between the inappropriate use of antibiotics and antibiotic resistance (AMR). Increased bacterial resistance is due in part to the inappropriate use of antimicrobial agents. The support of the pharmacist becomes important, and there is growing interest in antimicrobial stewardship to promote the appropriate and safe use of antimicrobials needed for the optimal selection of drugs, doses, durations of therapy, therapeutic drug monitoring (TDM), and implementations of cost containment strategies in Japan. Pharmacists should strive to disseminate the concept of \u201cchoosing wisely\u201d in relation to all medicines, implement further interventions, and put them into practice. In this article, we present data for antimicrobial stewardship and Japan\u2019s AMR action plan, focusing on how pharmacists should be involved in enabling physicians to choose antimicrobials wisely.<\/jats:p>","DOI":"10.3390\/antibiotics10111284","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:37:48Z","timestamp":1634827068000},"page":"1284","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Strategy for Hospital Pharmacists to Control Antimicrobial Resistance (AMR) in Japan"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-6507","authenticated-orcid":false,"given":"Yukihiro","family":"Hamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Hospital, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Ebihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Hospital, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Tokyo Women\u2019s Medical University Hospital, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, August 11). Global Action Plan on Antimicrobial Resistance. Available online: https:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/."},{"key":"ref_2","unstructured":"World Health Organization (2021, August 11). Global Action Plan on Antimicrobial Resistance. Available online: https:\/\/www.who.int\/antimicrobial-resistance\/publications\/global-action-plan\/en\/."},{"key":"ref_3","unstructured":"World Health Organization (2021, August 11). Country Self Assessment in Global Database for Antimicrobial Resistance. Available online: https:\/\/amrcountryprogress.org\/."},{"key":"ref_4","unstructured":"The Government of Japan (2021, August 11). NAP on Antimicrobial Resistance (AMR) 2016\u20132020, Available online: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000138942.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jgar.2016.07.002","article-title":"Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013)","volume":"7","author":"Muraki","year":"2016","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_6","first-page":"392","article-title":"Outpatient use of oral antibiotics and initiatives for appropriate use","volume":"69","author":"Ebihara","year":"2021","journal-title":"Jpn. J. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMp0911423","article-title":"Medicine\u2019s ethical responsibility for health care reform\u2014The Top Five list","volume":"362","author":"Brody","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"AMR Alliance Japan (2021, August 11). Recommendations toward the Next National Action Plan on Antimicrobial Resistance. Available online: https:\/\/hgpi.org\/en\/wp-content\/uploads\/sites\/2\/Action_Plan_Recommendations_ENG.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ajic.2016.05.008","article-title":"The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients","volume":"44","author":"Uematsu","year":"2016","journal-title":"Am. J. Infect. Control"},{"key":"ref_10","unstructured":"Ministry of Health, Labour and Welfare (2021, August 11). Japan Nosocomial Infections Surveillance Clinical Laboratory Division [CLSI 2012 Version], Available online: https:\/\/janis.mhlw.go.jp\/english\/report\/open_report\/2020\/3\/1\/ken_Open_Report_Eng_202000_clsi2012.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jiac.2019.10.017","article-title":"National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan","volume":"26","author":"Tsuzuki","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijid.2021.05.018","article-title":"Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: A population-level study, Japan, 2015\u20132018","volume":"108","author":"Tsuzuki","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","first-page":"377","article-title":"The utility of DALYs for public health policy and research: A reply","volume":"75","author":"Murray","year":"1997","journal-title":"Bull. World Health Organ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ajic.2018.04.214","article-title":"Effect of methicillin-resistant Staphylococcus aureus in Japan","volume":"46","author":"Uematsu","year":"2018","journal-title":"Am. J. Infect. Control."},{"key":"ref_16","unstructured":"Japanese Society of Chemotherapy\/Japanese Association for Infectious Diseases (2021, October 18). Practical Guidelines for the Management and Treatment of Infections Caused by MRSA (In Japanese). Available online: http:\/\/www.chemotherapy.or.jp\/guideline\/guideline_mrsa_2019.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1248\/bpb.b20-00605","article-title":"Trends of the Use of Anti-methicillin-Resistant Staphylococcus aureus Agents in Japan Based on Sales Data from 2006 to 2015","volume":"43","author":"Goto","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s15010-010-0001-8","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: Which infection control measures are taken?","volume":"38","author":"Hansen","year":"2010","journal-title":"Infection"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.ajic.2012.12.018","article-title":"Trend of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in an institution with a high rate of MRSA after the reinforcement of antibiotic stewardship and hand hygiene","volume":"41","author":"Kim","year":"2013","journal-title":"Am. J. Infect. Control"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5694\/j.1326-5377.2005.tb07151.x","article-title":"Efficacy of an alcohol\/chlorhexidine hand hygiene program in a hospital with high rates of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection","volume":"183","author":"Johnson","year":"2005","journal-title":"Med. J. Aust."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0195-6701(03)00293-7","article-title":"Performance feedback of hand hygiene, using alcohol gel as the skin decontaminant, reduces the number of inpatients newly affected by MRSA and antibiotic costs","volume":"56","author":"MacDonald","year":"2004","journal-title":"J. Hosp. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1017\/S0950268813001374","article-title":"Impact of an enhanced antibiotic stewardship on reducing methicillin-resistant Staphylococcus aureus in primary and secondary healthcare settings","volume":"142","author":"Aldeyab","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e006596","DOI":"10.1136\/bmjopen-2014-006596","article-title":"Turning the tide or riding the waves? Impacts of antibiotic stewardship and infection control on MRSA strain dynamics in a Scottish region over 16 years: Non-linear time series analysis","volume":"5","author":"Lawes","year":"2015","journal-title":"BMJ Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1742-1241.2012.02999.x","article-title":"Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese university hospital","volume":"66","author":"Niwa","year":"2012","journal-title":"J. Clin. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13065","DOI":"10.1111\/ijcp.13065","article-title":"Evaluation of treatment outcomes of patients with MRSA bacteremia following antimicrobial stewardship programs with pharmacist intervention","volume":"72","author":"Ohashi","year":"2018","journal-title":"Int. J. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiac.2020.10.014","article-title":"Comparison of trough concentration and area under the curve of vancomycin associated with the incidence of nephrotoxicity and predictors of a high trough level","volume":"27","author":"Suzuki","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2021.07.018","article-title":"Candidates for area under the time-concentration curve-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients","volume":"27","author":"Hashimoto","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1080\/10408398.2015.1077192","article-title":"Antimicrobial resistance: A global emerging threat to public health systems","volume":"57","author":"Ferri","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2017.21550","article-title":"The drug-resistant bacteria that pose the greatest health threats","volume":"543","author":"Willyard","year":"2017","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/CMR.00023-13","article-title":"Trends in human fecal carriage of extended-spectrum \u03b2-lactamases in the community: Toward the globalization of CTX-M","volume":"26","author":"Woerther","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.meegid.2018.04.005","article-title":"Current epidemiology, genetic evolution and clinical impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"61","author":"Chong","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.14740\/jocmr3928","article-title":"Change in the Antimicrobial Resistance Profile of Extended-Spectrum \u03b2-Lactamase-Producing Escherichia coli","volume":"11","author":"Miyazaki","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ejhpharm-2018-001820","article-title":"Antimicrobial resistance (AMR)","volume":"26","author":"Amann","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_35","unstructured":"FAO (2021, August 11). The FAO Action Plan on Antimicrobial Resistance 2016\u20132020. Available online: http:\/\/www.fao.org\/3\/a-i5996e.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nishiyama, M., Praise, S., Tsurumaki, K., Baba, H., Kanamori, H., and Watanabe, T. (2021). Prevalence of Antibiotic-Resistant Bacteria ESKAPE among Healthy People Estimated by Monitoring of Municipal Wastewater. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050495"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jiac.2021.03.012","article-title":"Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU)","volume":"27","author":"Wada","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2016.02.004","article-title":"Prevalence and risk factors of infections caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Enterobacteriaceae","volume":"22","author":"Nakai","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/jgid.jgid_72_17","article-title":"Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae","volume":"10","author":"Tulara","year":"2018","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.2016.4151","article-title":"Prevalence of Inappropriate Antibiotic Prescriptions among US Ambulatory Care Visits, 2010\u20132011","volume":"315","author":"Hersh","year":"2016","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4065\/mcp.2011.0358","article-title":"Antimicrobial stewardship","volume":"86","author":"Doron","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2020.11.158","article-title":"The effects of Japan\u2019s National Action Plan on Antimicrobial Resistance on antimicrobial use","volume":"103","author":"Kusama","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jiac.2020.10.010","article-title":"The effectiveness of prescription support and treatment reporting system on the appropriate usage of oral third-generation cephalosporins","volume":"27","author":"Kato","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_46","unstructured":"World Health Organization (2021, August 01). WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https:\/\/www.who.int\/news-room\/detail\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","article-title":"In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmid-mediated AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"84","author":"Matsumura","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-020-02977-8","article-title":"Pharmacokinetics\/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model","volume":"38","author":"Tashiro","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.ijid.2012.09.010","article-title":"The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"17","author":"Doi","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fukuchi, T., Iwata, K., Kobayashi, S., Nakamura, T., and Ohji, G. (2016). Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1770-1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jiac.2021.07.009","article-title":"Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"27","author":"Hamada","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3314\/mmj.17-00014","article-title":"National Trends in the Distribution of Candida Species Causing Candidemia in Japan from 2003 to 2014","volume":"59","author":"Kakeya","year":"2018","journal-title":"Med. Mycol. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12519-019-00259-x","article-title":"Clinical features in proven and probable invasive fungal disease in children and adolescents at a pediatric referral center: A 5-year experience","volume":"15","author":"Kishimoto","year":"2019","journal-title":"World J. Pediatr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1248\/bpb.b20-00302","article-title":"Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015","volume":"43","author":"Kawabe","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/jac\/dkw395","article-title":"The role of the multidisciplinary team in antifungal stewardship","volume":"71","author":"Agrawal","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21505594.2016.1226721","article-title":"Antifungal stewardship considerations for adults and pediatrics","volume":"8","author":"Hamdy","year":"2017","journal-title":"Virulence"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jiac.2019.01.015","article-title":"The effects of antifungal stewardship programs at a tertiary-care teaching hospital in Japan","volume":"25","author":"Kawaguchi","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jiac.2019.09.016","article-title":"Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities","volume":"26","author":"Samura","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_61","unstructured":"Hamada, Y., Ebihara, F., Kimura, T., and Kikuchi, K. (2019, January 29). In Proceedings of the 63th Annual Meeting of the Japanese Society for Medical Mycology, Chiba, Japan. Available online: https:\/\/www.mycology-jp.org\/en\/."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID guideline for the diagno-sis and management of Candida diseases 2012: Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: Experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1600-6143.2012.04042.x","article-title":"Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients","volume":"12","author":"Luong","year":"2012","journal-title":"Am. J. Transpl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","first-page":"739","article-title":"Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med. Wkly."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study con-ducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hanai, Y., Hamada, Y., Kimura, T., Matsumoto, K., Takahashi, Y., Fujii, S., Nishizawa, K., Miyazaki, Y., and Takesue, Y. (2021). Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 \u03bcg\/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis. J. Fungi, 7.","DOI":"10.3390\/jof7040306"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jiac.2020.11.014","article-title":"Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic re-view and meta-analysis","volume":"27","author":"Hanai","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Simon, L., D\u00e9m\u00e9autis, T., Dupont, D., Kramer, R., Garnier, H., Durieu, I., S\u00e9n\u00e9chal, A., Reix, P., Couraud, S., and Devouassoux, G. (2021). Azole resistance in Aspergillus fumigatus isolates from respiratory specimens in Lyon University Hospitals, France: Prevalence and mechanisms involved. Int. J. Antimicrob. Agents, Online ahead of print.","DOI":"10.1016\/j.ijantimicag.2021.106447"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chen, P.Y., Chuang, Y.C., Wu, U.I., Sun, H.Y., Wang, J.T., Sheng, W.H., Chen, Y.C., and Chang, S.C. (2021). Mechanisms of Azole Resistance and Trailing in Candida tropicalis Bloodstream Isolates. J. Fungi, 7.","DOI":"10.3390\/jof7080612"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.23736\/S0375-9393.20.14112-9","article-title":"PROSAFE: A European endeavor to improve quality of critical care medicine in seven countries","volume":"86","author":"Finazzi","year":"2020","journal-title":"Minerva Anestesiol"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1284\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:20:10Z","timestamp":1760167210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["antibiotics10111284"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10111284","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}